Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT07800520
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • OAT
  • Opioid Use Disorder

Eligibility Criteria

Sex
ALL
Age
25 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • [11C]OMAR — DRUG
    For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.

Study Details

The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls.

Key Dates

First listed
Sep 2, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2030
Completion
Aug 31, 2030

Study Design

Enrollment
110 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Other: Healthy Volunteers
    Healthy volunteers with no current or past major medical or psychiatric history
  • Other: Opioid Use Disorder in Opioid Agonist Therapy (OAT)
    Patients diagnosed with opioid use disorder during the early phase of opioid agonist therapy

Primary Outcome Measure

CB1R Availability [ Time Frame: Day 7 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Connecticut Mental Health Center, Clinical Neuroscience Research UnitNew HavenConnecticut06519
Abigail Dewey
[email protected]
475-441-4190
Anahita Bassir Nia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By research site
Connecticut Mental Health Center, Clinical Neuroscience Research Unit· New Haven, CT

Related Studies